Page last updated: 2024-09-04

satavaptan and Body Weight

satavaptan has been researched along with Body Weight in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bruha, R; Dudley, F; Ginès, P; Terg, R; Watson, H; Wong, F; Zarski, JP	1
Aronson, D; Krum, H; Mueller, M; Verbalis, JG	1
Abassi, ZA; Abu-Saleh, N; Azzam, ZS; Bishara, B; Hoffman, A; Karram, T; Nitecki, S; Rubinstein, I; Shiekh, H; Winaver, J	1

Trials

2 trial(s) available for satavaptan and Body Weight

Article	Year
Clinical trial: short-term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia--a randomized, double-blind, placebo-controlled study. Alimentary pharmacology & therapeutics, 2010, Volume: 31, Issue:8 Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Ascites; Body Weight; Diuretics; Double-Blind Method; Drug Combinations; Female; Furosemide; Humans; Liver Cirrhosis; Male; Middle Aged; Morpholines; Prospective Studies; Spiro Compounds; Spironolactone; Treatment Outcome	2010
Short- and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2-receptor antagonist: the DILIPO study. European journal of heart failure, 2011, Volume: 13, Issue:3 Topics: Adult; Aged; Antidiuretic Hormone Receptor Antagonists; Body Weight; Double-Blind Method; Female; Heart Failure; Humans; Hyponatremia; Kaplan-Meier Estimate; Male; Middle Aged; Morpholines; Sodium; Spiro Compounds; Treatment Outcome; Vasopressins; Young Adult	2011

Article

Year

Clinical trial: short-term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia--a randomized, double-blind, placebo-controlled study.

Alimentary pharmacology & therapeutics, 2010, Volume: 31, Issue:8

Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Ascites; Body Weight; Diuretics; Double-Blind Method; Drug Combinations; Female; Furosemide; Humans; Liver Cirrhosis; Male; Middle Aged; Morpholines; Prospective Studies; Spiro Compounds; Spironolactone; Treatment Outcome

2010

Short- and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2-receptor antagonist: the DILIPO study.

European journal of heart failure, 2011, Volume: 13, Issue:3

Topics: Adult; Aged; Antidiuretic Hormone Receptor Antagonists; Body Weight; Double-Blind Method; Female; Heart Failure; Humans; Hyponatremia; Kaplan-Meier Estimate; Male; Middle Aged; Morpholines; Sodium; Spiro Compounds; Treatment Outcome; Vasopressins; Young Adult

2011

Other Studies

1 other study(ies) available for satavaptan and Body Weight

Article	Year
Effects of novel vasopressin receptor antagonists on renal function and cardiac hypertrophy in rats with experimental congestive heart failure. The Journal of pharmacology and experimental therapeutics, 2008, Volume: 326, Issue:2 Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Body Weight; Cardiomegaly; Disease Models, Animal; Diuresis; Drug Administration Schedule; Heart Failure; Indoles; Kidney Function Tests; Male; Morpholines; Organ Size; Osmolar Concentration; Pyrrolidines; Rats; Rats, Sprague-Dawley; Sodium; Spiro Compounds; Vasoconstriction	2008

Article

Year

Effects of novel vasopressin receptor antagonists on renal function and cardiac hypertrophy in rats with experimental congestive heart failure.

The Journal of pharmacology and experimental therapeutics, 2008, Volume: 326, Issue:2

Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Body Weight; Cardiomegaly; Disease Models, Animal; Diuresis; Drug Administration Schedule; Heart Failure; Indoles; Kidney Function Tests; Male; Morpholines; Organ Size; Osmolar Concentration; Pyrrolidines; Rats; Rats, Sprague-Dawley; Sodium; Spiro Compounds; Vasoconstriction

2008